Roivan­t's ul­cer­a­tive col­i­tis drug from Pfiz­er shows promis­ing da­ta in ear­ly read­out

Roivant’s ul­cer­a­tive col­i­tis drug ac­quired from Pfiz­er last month has al­ready pro­duced pos­i­tive da­ta in the first read­out of the Phase IIb tri­al.

The com­pa­ny is now plan­ning for a Phase III test, claim­ing in a press re­lease that the drug has “best-in-in­di­ca­tion po­ten­tial” as a first- or sec­ond-line treat­ment. The tri­al in­clud­ed pa­tients who had re­ceived pri­or ther­a­py, in­clud­ing an­ti-TNF drugs, steroids, JAK in­hibitors and oth­er stan­dard treat­ments, and some pa­tients had a bio­mark­er as­so­ci­at­ed with the dis­ease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN